Formenti and colleagues have recently reported clinical outcomes and translational readouts from a trial that seeks to address this question using anti-CTLA-4 immunotherapy and palliative radiation in patients with non-small cell lung cancer (NSCLC) [1]. Here, CTLA4 is linked to non-small cell lung carcinoma.